Testing
We understand that genetic information often outpaces the availability of diagnostic assays currently available. Therefore, when appropriate, we are happy to provide custom re-sequencing assays . If you are looking to request a specific test not currently listed in GeneTests, please contact our laboratory manager, Dan Dykas at dnalab@yale.edu or (203) 785-5745 to arrange for this service.
Tests
- BRCA1/2 Common Jewish Mutations – CPT 81212
- Genes: BRCA1 (17q21) and BRCA2 (13q12.3)
- Methods: PCR and restriction enzyme digest screen for two mutations in BRCA1 (185delAG and 5382insC) and one mutation in BRCA2 (6174delT). Mutation confirmation by direct sequencing.
- Indications: Jewish ancestry with a history of breast and ovarian cancer.
- Turnaround Time: Approximately 2 weeks (screen)
- BRCA1/2 Familial Mutations – CPT 81215 (SS BRCA1) CPT 81217 (SS BRCA2)
- Genes: BRCA1 (17q21) and BRCA2 (13q12.3)
- Methods: PCR followed by direct sequencing.
- Indications: Known familial mutations in BRCA1 or BRCA2
- Turnaround Time: Approximately 2-4 weeks
- Fragile X-Syndrome (Fragile Site Mental Retardation 1) - CPT 81243
- Gene: FMR1 Cytoband: Xq27.3
- Methods and queried regions: PCR, determination of CGG-repeat-length, southern blot
- Indications: Undiagnosed mental retardation, autism
- Turnaround Time: Approximately 2 weeks
- Gorlin Syndrome (NBCCS, BCNS) - CPT 81479
- Gene: PTCH
- Cytoband: 9q22.3
- Methods and queried regions: Direct sequencing of coding exons (1B-23).
- Indications: Basal cell carcinoma, palmar and plantar pits, odontogenic keratocysts, calcification of falx cerebri, bifid ribs, ovarian fibroma.
- Turnaround Time: Approximately 8-12 weeks
- Hereditary Melanoma – CPT 81404
- Genes: CDKN2A (p16) and CDK4
- Cytobands: 9p21 and 12q14
- Direct sequencing of entire coding region of CDKN2A and exon 2 of CDK4.
- Indications: Family history of melanoma
- Turnaround Time: Approximately 4-6 weeks
- Medium chain acyl dehydrogenase deficiency (MCADD) - CPT 81406
- Gene: ACADM Cytoband: 1p31
- Methods: PCR and restriction enzyme digest screen for A985G mutation, Direct sequencing of coding exons (1-12)
- Indications: Lethargy, vomiting, coma, hypoglycemia, seizures, cardiac arrest.
- Turnaround Time: Approximately 2 weeks (A985G screen)
- Approximately 4 weeks (full sequence)
- Multiple Endocrine Neoplasia Type I (MEN1) - CPT 81405
- Gene: MEN1
- Cytoband: 11q13
- Direct sequencing of coding exons (2-10)
- Indications: Pancreatic, parathyroid, and pituitary tumors, hyperparathyroidism, carcinoid, positive family history
- Turnaround Time: Approximately 4-6 weeks
- Multiple Endocrine Neoplasia Type II (MEN 2) - CPT 81405
- Gene: RET-protooncogene
- Cytoband: 10q11.2
- Methods and queried regions: Direct sequencing of exons 10, 11, 13, 14, 15, and 16
- Indications: Medullary thyroid carcinoma, isolated or associated with pheochromocytoma, hyperparathyroidism, ganglioneuromatosis, positive family history
- Turnaround Time: Approximately 4-6 weeks
- Ornithine Transcarbamylase Deficiency (OTCD) - CPT 81405
- Gene: OTC
- Cytoband: Xp21.1
- Methods and queried regions: Direct sequencing of coding exons (1-10).
- Indications: Hyperammonemia, aversion to dietary protein, elevated orotic acid.
- Turnaround Time: Approximately 4-6 weeks
- Prader-Willi (PWS) and Angelman (AS) Syndromes (BWS) - CPT 81331
- Etiology: Imprinting phenomena: Loss of function of paternal (PWS) or maternal (AS) copy of 15q11-13 (SNRPN gene)
- Testing: Methylation specific PCR.
- Turnaround Time: Approximately 2-4weeks
- PTEN Testing – CPT 81321
- Gene: PTEN
- Cytoband: 10q 23.31
- Methods and queried regions: PCR of coding region and promotor followed by direct sequencing.
- Indications: Cowden Syndrome, Bannayan-Riley-Ruvalcaba Syndrome, Proteus and Proteus-Like Syndrome.
- Turnaround Time: Approximately 4-6 weeks
- EXTENDED GENE PANEL - CPT code based on genes tested
Multi-gene panel. Contact Laboratory for details
Sample Submission Forms
Lab Accreditation
- CAP Number: 1191007 (CAP Certificate 2019-2021)
- CLIA Number: 07D0098275 (CLIA Certificate 2019-2021)